Table III.
Univariate and multivariate analysis of clinical parameters affecting the overall survival rate of patients with HCC.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Clinical parameters | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Age | 0.65 | 0.41–1.31 | 0.07 | NA | ||
| Sex | 1.58 | 0.92–2.69 | 0.09 | NA | ||
| Tumor size | 1.95 | 1.22–3.31 | 0.01 | 1.06 | 0.49–2.28 | 0.89 |
| No. of tumors | 1.24 | 0.68–2.26 | 0.49 | NA | ||
| Edmondson grade | 2.56 | 1.71–3.84 | <0.01 | 2.44 | 1.28–4.63 | 0.01 |
| Distant metastasis | 4.82 | 2.55–9.11 | <0.01 | 2.99 | 1.07–8.35 | 0.04 |
| Microvascular infiltration | 2.11 | 1.25–3.56 | 0.01 | 1.35 | 0.65–2.80 | 0.42 |
| HBs antigen | 1.17 | 0.65–2.10 | 0.60 | NA | ||
| Cirrhosis | 1.15 | 0.70–1.91 | 0.58 | NA | ||
| AFP level | 2.51 | 1.40–4.52 | <0.01 | 1.72 | 0.83–3.56 | 0.14 |
| SLC17A9 expression | 0.59 | 0.36–0.96 | 0.03 | 1.81 | 0.99–3.77 | 0.04 |
HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; SLC17A9, solute carrier family 17 member 9; HR, hazard ratio; CI, confidence interval; NA, not applicable.